OlympiA: Adj Olaparib Post (Neo) Adjuvant Chemo in Pts with Germline BRCA1/BRCA2 & High Risk HER2-negative

Panelists discuss the OlympiA trial, evaluating adjuvant olaparib post-neoadjuvant chemotherapy in patients with germline BRCA1/BRCA2 mutations and high-risk HER2-negative breast cancer, and its impact on treatment outcomes.

EP: 1.INSEMA: No Axillary Surgery vs. Axillary SLNB in Pts With Early Invasive Breast Cancer

EP: 2.KEYONTE-522: Exploratory Biomarker Analysis in Periop Pembro vs. Placebo + Chemo

Now Viewing

EP: 3.OlympiA: Adj Olaparib Post (Neo) Adjuvant Chemo in Pts with Germline BRCA1/BRCA2 & High Risk HER2-negative

Recent Videos